A new report from the National Institutes of Health suggests that CBD, including Swissx products, can prevent and inhibit the SARS-CoV-2 infection in human lung cells when they’re used as a therapeutic treatment. Evidence that supports the celebrated doctor’s recommendation to use CBD to fight SARS-CoV-2, the agent responsible for COVID-19, is included in a new study published by The National Center for Biotechnology Information.
The study was conducted by Marsha Rosner and her colleagues a the University of Chicago. In an effort to suppress infection by the SARS-CoV-2 and other evolving pathogenic viruses, the scientists tested the antiviral potential of a number of small molecules that target host stress response pathways.
During the testing, CBD was found to potently blocks SARS-CoV-2 replication in lung epithelial cells. CBD was also found to reverse many of the effects the virus has on host gene transcription.
The test results also suggest that CBD administration is associated with a lower risk of SARS-CoV-2 infection in humans, as to regulates antiviral inflammatory responses. It was also found that CBD not only has to the potential to act as an antiviral agent at early stages of infection, but also protect people against an overactive immune system at later stages.
During the study, patients who were previously taking CBD showed to have significantly lower SARS-CoV-2 infection rates than the general population. That lower infection rate is believed to be a result of CBD and its metabolite, 7-OH-CBD, potently blocking SARS-CoV-2 replication in the lung cells. When used to treat infected cells, CBD inhibits viral gene expression and reverses many effects of SARS-CoV-2 on host gene transcription.
The study was conducted in response to the continued rapid spread of COVID-19, despite recent vaccine availability. The persistence of the virus is requiring the need for the development of new, more effective treatments.
SARS-CoV-2 is the seventh species of coronavirus known to infect people. The virus causes a range of symptoms from the common cold to more severe pathologies. CBD is one of the few therapies that have been identified as being able to stop those symptoms by blocking SARS-CoV-2 replication and viral production.
CBD has drug status in the U.S., which makes it viable as a legal, therapeutic treatment. Its garnered drug status, due to its viability against a variety of viruses as a result of its antiviral effects.
There are multiple means of ingesting Swissx CBD products, including inhalation and nasal delivery, which don’t lead to adverse health effects. In fact, research also suggests that because of its neuroprotective effects, CBD in all of its forms may help also relieve a variety of health ailments, from traumatic brain injuries to allergies, Psoriasis, high blood pressure, migraines, muscle tension, insomnia, autism, PTSD, Alzheimer’s, stress and anxiety.
